<PAGE>
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant /X/
Filed by a party other than the Registrant / /
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/X/ Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material Pursuant to 240.14a-11(c) or 240.14a-12
HEARTPORT, INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
/X/ No fee required.
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1)
and 0-11
(1) Title of each class of securities to which transaction applies:
------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
------------------------------------------------------------------------
(5) Total fee paid:
------------------------------------------------------------------------
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
------------------------------------------------------------------------
(3) Filing Party:
------------------------------------------------------------------------
(4) Date Filed:
------------------------------------------------------------------------
<PAGE>
[LOGO]
------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 28, 1997
------------------------
To Our Stockholders:
You are cordially invited to attend the Annual Meeting of Stockholders of
HEARTPORT, INC. (the "Company") which will be held at the Hotel Sofitel, 223
Twin Dolphin Drive, Redwood City, California, at 2:00 p.m. on May 28, 1997, for
the following purposes:
1. To elect two directors to serve for the ensuing three year term or until
their successors are elected and qualified;
2. To approve an amendment to the Company's 1996 Stock Option Plan to
increase the number of shares of Common Stock available for issuance
thereunder from 4,190,221 shares to 5,500,000 shares and to extend
eligibility for discretionary option grants to non-employee directors;
3. To approve an amendment to the Company's Employee Stock Purchase Plan
(the "Purchase Plan") to (i) provide for twenty-four month enrollment
periods; (ii) permit participants to contribute a maximum of 15% of
eligible cash compensation; and (iii) expand the types of compensation
eligible for withholding under the Purchase Plan;
4. To ratify the selection of Ernst & Young LLP as independent auditors for
the Company for the fiscal year ending December 31, 1997; and
5. To act upon such other business as may properly come before the meeting
or at any adjournment or postponement thereof.
The Board of Directors has fixed the close of business on March 31, 1997, as
the record date for determining those stockholders who will be entitled to vote
at the meeting. The stock transfer books will not be closed between the record
date and the date of the meeting.
Representation of at least a majority of all outstanding shares of Common
Stock of Heartport, Inc. is required to constitute a quorum. Accordingly, it is
important that your shares be represented at the meeting. WHETHER OR NOT YOU
PLAN TO ATTEND THE MEETING, PLEASE COMPLETE, DATE AND SIGN THE ENCLOSED PROXY
CARD AND RETURN IT IN THE ENCLOSED ENVELOPE. You may revoke your proxy at any
time prior to the time it is voted. If you attend the Annual Meeting and vote by
ballot, your proxy will be revoked automatically and only your vote at the
Annual Meeting will be counted.
Sincerely,
/s/ Wesley D. Sterman, M.D.
Wesley D. Sterman, M.D.
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Redwood City, California
April 30, 1997
<PAGE>
STOCKHOLDERS SHOULD READ THE ENTIRE PROXY STATEMENT
CAREFULLY PRIOR TO RETURNING THEIR PROXIES
------------------------
PROXY STATEMENT
FOR
ANNUAL MEETING OF STOCKHOLDERS OF
HEARTPORT, INC.
TO BE HELD MAY 28, 1997
------------------------
This Proxy Statement is furnished in connection with the solicitation by the
Board of Directors of HEARTPORT, INC. ("Heartport" or the "Company") of proxies
to be voted at the Annual Meeting of Stockholders which will be held at 2:00
p.m. on May 28, 1997, at the Hotel Sofitel, 223 Twin Dolphin Drive, Redwood
City, California, or at any adjournments or postponements thereof, for the
purposes set forth in the accompanying Notice of Annual Meeting of Stockholders.
This Proxy Statement and the proxy card were first mailed to stockholders on or
about April 30, 1997.
VOTING RIGHTS AND SOLICITATION
The close of business on March 31, 1997, was the record date for
stockholders entitled to notice of and to vote at the Annual Meeting. As of that
date, Heartport had 24,589,452 shares of common stock, $.001 par value per share
(the "Common Stock"), issued and outstanding, exclusive of treasury stock. All
of the shares of Common Stock outstanding on the record date are entitled to
vote at the Annual Meeting, and stockholders of record entitled to vote at the
meeting will have one (1) vote for each share so held on the matters to be voted
upon.
Shares of Common Stock represented by proxies in the accompanying form that
are properly executed and returned to Heartport will be voted at the Annual
Meeting of Stockholders in accordance with the stockholders' instructions
contained therein. In the absence of contrary instructions, shares represented
by such proxies will be voted FOR the election of each of the directors as
described herein under "Proposal 1--Election of Directors," FOR approval of the
amendment to the 1996 Stock Option Plan as described herein under "Proposal
2--Amendment to the 1996 Stock Option Plan," FOR approval of the amendment to
the Employee Stock Purchase Plan as described herein under "Proposal
3--Amendment to the Employee Stock Purchase Plan" and FOR ratification of the
selection of accountants as described herein under "Proposal 4--Ratification of
Selection of Independent Auditors." Management does not know of any matters to
be presented at this Annual Meeting other than those set forth in this Proxy
Statement and in the Notice accompanying this Proxy Statement. If other matters
should properly come before the meeting, the proxy holders will vote on such
matters in accordance with their best judgment. Any stockholder has the right to
revoke his or her proxy at any time before it is voted.
The entire cost of soliciting proxies will be borne by Heartport. Proxies
will be solicited principally through the use of the mails, but, if deemed
desirable, may be solicited personally or by telephone, telegraph or special
letter by officers and regular Heartport employees for no additional
compensation. The Company has engaged The First National Bank of Boston ("Bank
of Boston") to provide routine advice and services for proxy solicitation in
addition to other services. Bank of Boston will receive approximately $11,400
from the Company per annum for such advice and services. Arrangements may be
made with brokerage houses and other custodians, nominees and fiduciaries to
send proxies and proxy material to the beneficial owners of Common Stock, and
such persons may be reimbursed for their expenses.
1
<PAGE>
VOTES REQUIRED
PROPOSAL 1. Directors are elected by a plurality of the affirmative votes
cast by those shares present in person, or represented by proxy, and entitled to
vote at the Annual Meeting. The two nominees for director receiving the highest
number of affirmative votes will be elected. Abstentions and broker non-votes
will not be counted toward a nominee's total. Stockholders may not cumulate
votes in the election of directors.
PROPOSAL 2. Approval of the adoption of the amendment to the Company's 1996
Stock Option Plan requires the affirmative vote of a majority of those shares
present in person, or represented by proxy, and entitled to vote at the Annual
Meeting. Abstentions will be treated as votes against the proposal. Broker
non-votes will be treated as not entitled to vote on this matter and thus will
have no effect on the outcome of the vote.
PROPOSAL 3. Approval of the adoption of the amendment to the Company's
Employee Stock Purchase Plan requires the affirmative vote of a majority of
those shares present in person, or represented by proxy, and entitled to vote at
the Annual Meeting. Abstentions will be treated as votes against the proposal.
Broker non-votes will be treated as not entitled to vote on this matter and thus
will have no effect on the outcome of the vote.
PROPOSAL 4. Ratification of the appointment of Ernst & Young LLP as the
Company's independent auditors for the fiscal year ending December 31, 1997,
requires the affirmative vote of a majority of those shares present in person,
or represented by proxy, and cast either affirmatively or negatively at the
Annual Meeting. Abstentions and broker non-votes will not be counted as having
been voted on the proposal.
STOCKHOLDER PROPOSALS
Stockholder proposals intended to be considered at the 1998 Annual Meeting
of Stockholders must be received by Heartport no later than March 30, 1998 and
not prior to February 28, 1998. The proposal must be mailed to the Company's
principal executive offices, 200 Chesapeake Drive, Redwood City, California
94063, Attention: Corporate Secretary. Such proposals may be included in next
year's proxy statement if they comply with certain rules and regulations
promulgated by the Securities and Exchange Commission ("SEC") and certain
provisions contained in the Company's Bylaws.
MATTERS TO BE CONSIDERED AT ANNUAL MEETING
PROPOSAL 1
ELECTION OF DIRECTORS
The Company currently has authorized seven directors. In accordance with the
terms of the Company's Certificate of Incorporation, the Board of Directors is
divided into three classes; Class I, whose term will expire at the 1997 Annual
Meeting; Class II, whose term will expire at the annual meeting of stockholders
to be held in 1998; and Class III, whose term will expire at the annual meeting
of stockholders to be held in 1999. At the 1997 Annual Meeting, two directors
will be elected to serve until the Annual Meeting to be held in 2000 or until
his respective successor is elected and qualified. The Board of Directors has
selected two nominees as the nominees for Class I. The nominees for the Board of
Directors are both currently directors of the Company and are set forth below.
In the absence of contrary instructions, the proxy holders intend to vote all
proxies received by them in the accompanying form FOR the nominees for director
listed below. In the event any nominee is unable or declines to serve as a
director at the time of the Annual Meeting, the proxies will be voted for any
nominee who shall be designated by the present Board of Directors to fill the
vacancy. In the event that additional persons are nominated for election as
directors, the proxy holders intend to vote all proxies received by them for the
nominees listed
2
<PAGE>
below. As of the date of this Proxy Statement, the Board of Directors is not
aware of any nominee who is unable or will decline to serve as a director.
NOMINEES FOR TERM ENDING IN 2000
Set forth below is information regarding the nominees, including their ages,
the period during which they have served as directors, and information furnished
by them as to principal occupations and directorships held by them in
corporations whose shares are publicly registered.
<TABLE>
<CAPTION>
DIRECTOR
NAME SINCE AGE
- --------------------------------------------------------------------------- -------- ---
<S> <C> <C>
Frank M. Fischer........................................................... 1992 55
Petri T. Vainio, M.D., Ph.D................................................ 1992 37
</TABLE>
FRANK M. FISCHER has been a director of the Company since October, 1992. Mr.
Fischer has been the President and Chief Executive Officer and a director of
Ventritex, Inc., a manufacturer of implantable cardiac defibrillators, since
July, 1987. From May, 1977 until joining Ventritex, Mr. Fischer held various
positions with Cordis Corporation, a manufacturer of medical products, serving
most recently as President of the Implantable Products Division. Mr. Fischer
serves on the Board of Directors of Heartstream, Inc., a medical device company.
Mr. Fischer holds an M.S. in Management from Rensselaer Polytechnic Institute.
PETRI T. VAINIO, M.D., PH.D. has been a director of the Company since April,
1992. Dr. Vainio is a general partner of Sierra Ventures, a venture capital firm
he joined in 1988. He currently serves on the Board of Directors of Connective
Therapeutics, Inc., a biotechnology company. Dr. Vainio holds M.D. and Ph.D.
degrees from the University of Helsinki, Finland, and an M.B.A. from the
Graduate School of Business at Stanford University.
CONTINUING DIRECTORS
Set forth below is information regarding the continuing directors of the
Company, including their ages, the period in which they have served as
directors, and information furnished by them as to principal occupations and
directorships held by them in corporations whose shares are publicly registered.
<TABLE>
<CAPTION>
DIRECTOR
NAME SINCE AGE
- --------------------------------------------------------------------------- -------- ---
<S> <C> <C>
Robert V. Gunderson, Jr.................................................... 1995 45
Joseph S. Lacob............................................................ 1992 41
Wesley D. Sterman, M.D..................................................... 1991 36
John H. Stevens, M.D....................................................... 1991 36
Steven C. Wheelwright, Ph.D................................................ 1995 53
</TABLE>
WESLEY D. STERMAN, M.D. founded the Company with Dr. Stevens in May, 1991,
and has served as the Company's President and Chief Executive Officer since that
time. Prior to founding the Company, Dr. Sterman was founder, President and
Chief Executive Officer of EndoVascular Technologies, Inc., a medical device
manufacturer, from July, 1989 to September, 1991. Dr. Sterman has B.S. degrees
both in Biology and in Chemistry from Stanford University. Dr. Sterman received
an M.D. from the Stanford University School of Medicine and an M.B.A. from the
Graduate School of Business at Stanford University, where he was an Arjay Miller
Scholar.
ROBERT V. GUNDERSON, JR. has been a director of the Company since May, 1995.
Mr. Gunderson has been a partner of the law firm of Gunderson Dettmer Stough
Villeneuve Franklin & Hachigian, LLP, since its formation in September, 1995.
From May, 1988, until September, 1995, Mr. Gunderson was a partner of the law
firm of Brobeck, Phleger & Harrison, LLP. Mr. Gunderson holds an M.A. from
Stanford
3
<PAGE>
University, an M.B.A. in finance from the Wharton School, University of
Pennsylvania and a J.D. from the University of Chicago.
JOSEPH S. LACOB has been a director of the Company since April, 1992. Mr.
Lacob is a general partner of Kleiner Perkins Caufield & Byers ("Kleiner
Perkins"), a venture capital firm he joined in 1987. Prior to joining Kleiner
Perkins, he was Marketing Manager for Cetus Corporation, a biotechnology
company. Mr. Lacob serves as Chairman of the Board of Directors of CellPro,
Incorporated, and is a director of Pharmacyclics, Inc. and eight privately held
companies. Mr. Lacob holds a B.S. in Biochemistry from the University of
California at Irvine, a Masters in Public Health from the University of
California at Los Angeles, and an M.B.A. from the Graduate School of Business at
Stanford University.
JOHN H. STEVENS, M.D. founded the Company with Dr. Sterman in May, 1991, and
has been a director of the Company since that time. Formerly Chief Resident of
the Department of Cardiothoracic Surgery at the Stanford University School of
Medicine, and Senior Registrar in Cardiothoracic Surgery at the Great Ormond
Street Hospital for Sick Children in London, England, Dr. Stevens is now an
Associate Professor in the Department of Cardiothoracic Surgery at Stanford
University School of Medicine. Dr. Stevens earned B.U.S. and B.S. degrees in
Communications and Psychology from the University of Utah and an M.D. from the
Stanford University School of Medicine.
STEVEN C. WHEELWRIGHT, PH.D. has been a director of the Company since
January, 1995. Dr. Wheelwright currently serves as a senior associate dean at
the Graduate School of Business, Harvard University, where he has been a
professor since July, 1988. Dr. Wheelwright also served as a professor at the
Graduate School of Business, Harvard University, from August, 1985 to August,
1986. From August, 1986 to August, 1988, Dr. Wheelwright served as a professor
at the Graduate School of Business at Stanford University. Dr. Wheelwright is
also a member of the Board of Directors of Quantum Corporation, a mass storage
device company, T.J. International Corporation, an engineered wood products
company, and Alleghany-Ludlum Steel Corporation, a specialty steel company.
BOARD MEETINGS AND COMMITTEES
During the fiscal year ended December 31, 1996, the Board of Directors of
the Company held a total of nine (9) meetings. During this period, each director
attended or participated in at least 75% of the aggregate of (i) the total
number of meetings of the Board and (ii) the total number of meetings held by
all committees of the Board on which he was a member.
The Board of Directors has an Audit Committee and a Compensation Committee.
There is no nominating committee or committee performing the functions of such
committee.
The Audit Committee meets with the Company's financial management and its
independent accountants at various times during each year and reviews internal
control conditions, audit plans and results, and financial reporting procedures.
This Committee, consisting of Messrs. Gunderson, Lacob and Wheelwright, held one
(1) meeting during fiscal 1996.
The Compensation Committee reviews and approves the Company's compensation
arrangements for management. This Committee, consisting of Messrs. Fischer,
Vainio and Wheelwright, held three (3) meetings during fiscal 1996.
DIRECTOR COMPENSATION
The Company's directors are not compensated for any meetings that they
attend. However, each of the Company's directors, in exchange for his services
as a director, was granted stock options to purchase shares of Common Stock. The
Company's directors were granted the following options to purchase shares of
Common Stock in April, 1995, at an exercise price of $0.375 per share: Dr.
Wesley D. Sterman and Dr. John H. Stevens were granted options to purchase
640,000 shares and 192,000 shares, respectively; each of the options are
immediately exercisable and the shares vest monthly over a five year period
4
<PAGE>
beginning from the fifth anniversary of the date of hire or the date the
individual became a director, as applicable. Each of the Company's outside
directors was granted options to purchase 80,000 shares on April 1, 1995 at an
exercise price of $0.375 per share. Each director except Joseph S. Lacob has
exercised in full his respective option grants. All of the foregoing options
granted to the directors are immediately exercisable and the director vests in
the shares monthly over a five year period. In addition, the Company's 1996
Stock Option Plan provides for automatic grants to non-employee directors. See
"Proposal 2-- Amendment to the 1996 Stock Option Plan--Automatic Option Grant
Program." For additional information concerning amounts paid to directors, see
"Certain Transactions."
RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board of Directors recommends that the stockholders vote FOR the
election of each of the above nominees.
PROPOSAL 2
AMENDMENT TO THE 1996 STOCK OPTION PLAN
The stockholders are being asked to vote on a proposal to approve an
amendment to the Heartport, Inc. 1996 Stock Option Plan (the "Option Plan")
which was adopted by the Board of Directors on October 21, 1996 to (i) increase
the number of shares of Common Stock available for issuance under the Option
Plan by 1,309,779 shares to a total of 5,500,000 shares of Common Stock, (ii)
extend eligibility for discretionary option grants to non-employee directors and
(iii) make certain other changes to delete provisions made inapplicable by
changes to SEC rules governing option grants to officers and directors subject
to the short-swing profit rules of the Federal securities laws. In the absence
of contrary instructions, the proxy holders intend to vote all proxies received
by them FOR the amendment to the Option Plan. The following is a description of
the Option Plan, as amended. The Company established the Option Plan as a
successor to the 1993 Stock Option Plan (the "1993 Plan") to provide a means
whereby employees, officers, directors, consultants, and independent advisors of
the Company or parent or subsidiary corporations may be given an opportunity to
purchase shares of Common Stock. The Option Plan was adopted by the Board on
February 26, 1996 and approved by the stockholders on April 10, 1996. The Board
believes that option grants under the Option Plan play an important role in the
Company's efforts to attract, employ, and retain employees, directors, and
consultants of outstanding ability.
SUMMARY OF 1996 STOCK OPTION PLAN
The principal terms and provisions of the Option Plan are summarized below.
The summary, however, is not intended to be a complete description of all the
terms of the Option Plan. A copy of the Option Plan will be furnished by the
Company to any stockholder upon written request to the Secretary of the Company
at the executive offices in Redwood City, California.
STRUCTURE. The Option Plan contains two separate equity incentive programs:
(i) a Discretionary Option Grant Program under which eligible persons may be
granted stock options to purchase shares of Common Stock, and (ii) an Automatic
Option Grant Program under which option grants will be made at specified
intervals to the non-employee Board members.
ADMINISTRATION. The Option Plan is currently administered by the
Compensation Committee of the Board of Directors (the "Committee"). The Option
Plan may also be administered by the Board or a secondary committee comprised of
one or more Board members with respect to optionees who are not executive
officers subject to the short-swing profit rules of the Federal securities laws.
Committee members serve for such period of time as the Board may determine. The
Committee (or Board or secondary committee to the extent acting as plan
administrator) has full authority (subject to the express provisions of the
Option Plan) to determine the eligible individuals who are to receive grants
under the Option Plan, the number of shares to be covered by each granted
option, the date or dates on which the option is to become
5
<PAGE>
exercisable, the maximum term for which the option is to remain outstanding,
whether the granted option will be an incentive stock option ("Incentive
Option") which satisfies the requirements of Section 422 of the Internal Revenue
Code (the "Code") or a non-statutory option not intended to meet such
requirements, and the remaining provisions of the option grant.
Administration of the Automatic Option Grant Program is self-executing in
accordance with the terms of that program, and no plan administrator shall
exercise any discretionary functions with respect to grants made thereunder.
ELIGIBILITY. All employees (including officers), consultants and
independent contractors who render services to the Company or its parent or
subsidiary corporations (whether now existing or subsequently established) are
eligible to receive option grants under the Discretionary Option Grant Program.
A non-employee member of the Board of Directors of the Company or any parent or
subsidiary corporation is also eligible for option grants under the
Discretionary Option Grant Program. Prior to amendment of the Option Plan on
October 21, 1996, non-employee members of the Board were eligible solely for
automatic grants under the Automatic Option Grant Program of the Option Plan.
SECURITIES SUBJECT TO OPTION PLAN. The number of shares of Common Stock
which may be issued over the term of the Option Plan shall not exceed 5,500,000
shares, including an increase of 1,309,779 shares, which is the subject of this
Proposal No. 2. Such share reserve will be subject to further adjustment in the
event of subsequent changes to the capital structure of the Company. The shares
may be made available either from the Company's authorized but unissued Common
Stock or from Common Stock reacquired by the Company, including shares purchased
on the open market.
In no event, however, may any one participant in the Option Plan acquire
shares of Common Stock under the Option Plan in excess of 1,000,000 shares over
the term of the Option Plan, exclusive of option grants received prior to
January 1, 1996.
Should an option expire or terminate for any reason prior to exercise in
full, including options incorporated from the 1993 Plan, the shares subject to
the portion of the option not so exercised will be available for subsequent
option grants under the Option Plan.
The holder of an option shall have no stockholder rights with respect to the
shares subject to the option until such person shall have exercised the option,
paid the exercise price and become the stockholder of record of the purchased
shares. Options are not assignable or transferable other than by will or the
laws of descent and distribution, and during the optionee's lifetime, the option
may be exercised only by the optionee. However, the October 21, 1996 amendment
permits non-statutory options to be assigned (1) to an optionee's family member
or a trust for the benefit of a family member provided notice is given to the
Committee or (2) to other individuals or entities with the prior consent of the
Committee.
DISCRETIONARY OPTION GRANT PROGRAM
PRICE AND EXERCISABILITY. The option exercise price per share may not be
less than eighty-five percent (85%) of the fair market value of Common Stock on
the grant date. Options granted under the Discretionary Option Grant Program
become exercisable at such time or times, and during such period, as the
Committee may determine and set forth in the instrument evidencing the option
grant. In any event, options granted under the Option Plan may not have a term
in excess of ten years.
The exercise price for options granted under the Option Plan may be paid in
cash or in outstanding shares of Common Stock. Options may also be exercised on
a cashless basis through the same-day sale of the purchased shares. The
Committee may also permit the optionee to pay the exercise price through a
promissory note payable in installments over a period of years. The amount
financed may include any Federal or state income and employment taxes incurred
by reason of the option exercise.
6
<PAGE>
TERMINATION OF SERVICE. Any option held by the optionee at the time of
cessation of service will not remain exercisable beyond the designated
post-service exercise period. Under no circumstances may any option be exercised
after the specified expiration date of the option term. Each such option will
normally, during such limited period, be exercisable only to the extent of the
number of shares of Common Stock in which the optionee is vested at the time of
cessation of service. The optionee will be deemed to continue in service for so
long as such individual performs services for the Company (or any parent or
subsidiary corporation), whether as an employee, independent contractor,
consultant or Board member.
The Committee has complete discretion to extend the period following the
optionee's cessation of service during which his or her outstanding options may
be exercised and/or to accelerate the exercisability of such options in whole or
in part. Such discretion may be exercised at any time while the options remain
outstanding, whether before or after the optionee's actual cessation of service.
The shares of Common Stock acquired upon the exercise of one or more options
may be subject to repurchase by the Company at the original exercise price paid
per share upon the optionee's cessation of service prior to vesting in such
shares. The Committee has complete discretion in establishing the vesting
schedule to be in effect for any such unvested shares and may cancel the
Company's outstanding repurchase rights with respect to those shares at any
time, thereby accelerating the vesting of the shares subject to the canceled
rights.
INCENTIVE OPTIONS. Incentive Options may only be granted to individuals who
are employees of the Company or its parent or subsidiary corporations. During
any calendar year, the aggregate fair market value (determined as of the grant
date(s)) of Common Stock for which one or more options granted to any employee
under the Option Plan (or any other option plan of the Company or its parent or
subsidiary corporations) may for the first time become exercisable as Incentive
Options under Section 422 of the Code shall not exceed $100,000.
If an employee to whom an Incentive Option is granted is the owner of stock
possessing more than ten percent (10%) of the total combined voting power of all
classes of stock of the Company or any of its parent or subsidiary corporations,
then the option price per share will be at least one hundred and ten percent
(110%) of the fair market value per share on the grant date, and the option term
will not exceed five years, measured from the grant date.
TANDEM STOCK APPRECIATION RIGHTS. The Committee is authorized to issue
tandem stock appreciation rights in connection with option grants under the
Discretionary Option Grant Program. Tandem stock appreciation rights provide the
holders with the right, subject to the Committee's approval, to surrender their
options for a distribution from the Company equal in amount to the excess of (a)
the fair market value of the vested shares of Common Stock subject to the
surrendered option over (b) the aggregate exercise price payable for such
shares. Such distribution may, at the discretion of the Committee, be made in
cash or in shares of Common Stock or partly in shares of Common Stock and partly
in cash.
AUTOMATIC OPTION GRANT PROGRAM
Under the Automatic Option Grant Program, non-employee Board members will
receive option grants at designated dates during their period of Board service.
These special grants may be summarized as follows:
Each individual who first becomes a non-employee Board member after the date
of the initial public offering, whether through election by the stockholders
or appointment by the Board, will automatically be granted, at the time of
such initial election or appointment, a non-statutory stock option to
purchase 32,000 shares of Common Stock.
On the date of each Annual Stockholders Meeting beginning with the meeting
scheduled for May 28, 1997, each individual who is a non-employee Board
member and continues to serve as a Board member after such meeting shall
automatically be granted a non-statutory stock option to purchase
7
<PAGE>
6,400 shares of Common Stock, whether or not that individual is standing for
re-election at that meeting. A newly elected or appointed non-employee Board
member shall receive his or her first annual grant at the first Annual
Meeting occurring on or after the first anniversary of the date of the
director's initial appointment or election.
Each option grant under the Automatic Option Grant Program will be subject
to the following terms and conditions:
(1) The option price per share will be equal to 100% of the fair market
value per share of Common Stock on the automatic grant date and each option
is to have a maximum term of ten years measured from the grant date.
(2) Each automatic option granted before October 21, 1996 will be
immediately exercisable for all of the option shares, but the shares
purchasable under the option will be subject to repurchase at the original
exercise price in the event the optionee's Board service should cease prior
to full vesting. With respect to each initial grant, the repurchase right
will lapse and the optionee will vest in a series of five (5) successive
annual installments, measured from the grant date, provided such optionee
continues service as a Board member. Each initial option granted after
October 21, 1996 will become exercisable in a series of five (5) successive
annual installments over the optionee's Board service measured from the
grant date. Each annual grant will become exercisable in full on the fifth
anniversary of the automatic grant date.
(3) The option will remain exercisable for a twelve month period
following the optionee's termination of service as a Board member for any
reason. Should the optionee die while serving as a Board member or during
the twelve month period following his or her cessation of Board service,
then such options may be exercised during the twelve month period following
such optionee's cessation of service by the personal representatives of the
optionee's estate or the person to whom the grant is transferred by the
optionee's will or the laws of inheritance. In no event, however, may the
option be exercised after the expiration date of the option term. During the
applicable exercise period, the option may not be exercised for more than
the number of vested shares (if any) for which it is exercisable at the time
of the optionee's cessation of Board service.
(4) The option shares will become fully exercisable and fully vested in
the event of a Corporate Transaction (as defined below) or a Change in
Control (as defined below). The option shares will become fully exercisable
and fully vested in the event of the optionee's cessation of Board service
by reason of death or permanent disability.
(5) Upon the occurrence of a hostile tender offer, each option granted
before October 21, 1996 which has been held for at least six months shall be
automatically canceled (to the extent the optionee is vested in such option
shares) and the optionee will in return be entitled to a cash distribution
from the Company in an amount per canceled option share equal to the excess
of (i) the highest reported price per share of Common Stock paid in the
tender offer or, if greater, the fair market value per share of Common Stock
over (ii) the option exercise price payable per share.
(6) Option grants under the Automatic Option Grant Program will be made
in strict compliance with the express provisions of that program. The
remaining terms and conditions of the options will in general conform to the
terms described above for option grants under the Discretionary Option Grant
Program and will be incorporated into the option agreement evidencing the
automatic grant.
8
<PAGE>
GENERAL PROVISIONS
ACCELERATION OF OPTIONS/TERMINATION OF REPURCHASE RIGHTS. Upon the
occurrence of either of the following transactions (a "Corporate Transaction"):
(i) the sale, transfer, or other disposition of all, or substantially
all, of the Company's assets in complete liquidation or dissolution of the
Company, or
(ii) a merger or consolidation in which securities possessing more than
fifty percent (50%) of the total combined voting power of the Company's
outstanding securities are transferred to a person or persons different from
the persons holding those securities immediately prior to such transaction,
each outstanding option under the Option Plan will, immediately prior to the
effective date of the Corporate Transaction, become fully exercisable for all of
the shares at the time subject to such option. However, an outstanding option
shall not accelerate if and to the extent: (a) such option is, in connection
with the Corporate Transaction, either to be assumed by the successor
corporation (or parent) or to be replaced with a comparable option to purchase
shares of the capital stock of the successor corporation (or parent), (b) such
option is to be replaced with a cash incentive program of the successor
corporation which preserves the spread existing on the unvested option shares at
the time of the Corporate Transaction and provides for subsequent payout in
accordance with the same vesting schedule applicable to such option, or (c) the
acceleration of such option is subject to other limitations imposed by the
Committee at the time of the option grant. Immediately following the
consummation of the Corporate Transaction, all outstanding options will
terminate and cease to be exercisable, except to the extent assumed by the
successor corporation.
Also upon a Corporate Transaction, the Company's outstanding repurchase
rights will terminate automatically and the shares of Common Stock subject to
those terminated rights shall vest in full unless assigned to the successor
corporation or accelerated vesting is precluded by other limitations imposed by
the Committee at the time the repurchase right is issued.
Any options which are assumed or replaced in the Corporate Transaction and
do not otherwise accelerate at that time shall automatically accelerate (and any
of the Company's outstanding repurchase rights which do not otherwise terminate
at the time of the Corporate Transaction shall automatically terminate and the
shares of Common Stock subject to those terminated rights shall immediately
vest) in the event the optionee's service should subsequently terminate by
reason of an involuntary or constructive termination within twelve months
following the effective date of such Corporate Transaction as if the optionee
remained in service for an additional twelve months following such termination.
Any options so accelerated shall remain exercisable for fully vested shares
until the earlier of (i) the expiration of the option term or (ii) the
expiration of the one year period measured from the effective date of the
employment termination.
The vesting acceleration provisions described above were extended to options
outstanding under the 1993 Plan by an amendment approved by the Committee on
March 12, 1997.
Upon the occurrence of the following transactions ("Change in Control"):
(i) any person or related group of persons (other than the Company or a
person that directly or indirectly controls, is controlled by, or is under
common control with, the Company) acquires beneficial ownership of more than
fifty percent (50%) of the Company's outstanding voting stock without the
Board's recommendation, or
(ii) there is a change in the composition of the Board over a period of
thirty-six consecutive months or less such that a majority of the Board
members ceases by reason of a proxy contest(s) to be comprised of
individuals who (a) have been Board members continuously since the beginning
of such period, or (b) have been elected or nominated for selection as Board
members by a majority of the Board in clause (a) who were still in office at
the time such election or nomination was approved by
9
<PAGE>
the Board, the Committee has the discretion to accelerate outstanding
options and terminate the Company's outstanding repurchase rights. The
Committee also has the discretion to accelerate outstanding options and
terminate the Company's outstanding repurchase rights upon the subsequent
termination of the optionee's service within a specified period following
the Change in Control.
The acceleration of options in the event of a Corporate Transaction or
Change in Control may be seen as an anti-takeover provision and may have the
effect of discouraging a merger proposal, a takeover attempt, or other efforts
to gain control of the Company.
VALUATION. For purposes of establishing the option price and for all other
valuation purposes under the Option Plan, the fair market value of a share of
Common Stock on any relevant date will be the closing price per share of Common
Stock on that date, as such price is reported on the Nasdaq National Market. The
fair market value on March 31, 1997 as reported on the Nasdaq National Market
was $24.50 per share.
CHANGE IN CAPITALIZATION. In the event any change is made to the Common
Stock issuable under the Option Plan by reason of any stock split, stock
dividend, combination of shares, exchange of shares, or other change affecting
the outstanding Common Stock as a class without the Company's receipt of
consideration, appropriate adjustments will be made to (i) the maximum number
and/or class of securities issuable under the Option Plan, (ii) the maximum
number and/or class of securities for which any one person may be granted
options and separately exercisable stock appreciation rights per calendar year
or over the term of the Option Plan, (iii) the number and/or class of securities
for which automatic option grants are to be subsequently made per director under
the Automatic Option Grant Program and (iv) the number and/or class of
securities and the exercise price per share in effect under each outstanding
option (including any option incorporated from the 1993 Plan) in order to
prevent the dilution or enlargement of benefits thereunder.
Each outstanding option which is assumed in connection with a Corporate
Transaction will be appropriately adjusted to apply and pertain to the number
and class of securities which would otherwise have been issued, in consummation
of such Corporate Transaction, to the option holder had the option been
exercised immediately prior to the Corporate Transaction. Appropriate
adjustments will also be made to the option price payable per share and to the
class and number of securities available for future issuance under the Option
Plan on both an aggregate and a per-participant basis.
OPTION PLAN AMENDMENTS. The Board may amend or modify the Option Plan in
any and all respects whatsoever. The Board may not, without the approval of the
Company's stockholders, (i) materially increase the maximum number of shares
issuable under the Option Plan (except in connection with certain changes in
capitalization), or (ii) materially modify the eligibility requirements for
option grants. Prior to the amendment of the Option Plan which is the subject of
this Proposal No. 2, the Automatic Option Grant Program could not be amended
more often than every six months and the Board could not, without stockholder
approval, amend the Option Plan to increase materially the benefits accruing to
participants under the Option Plan.
Unless sooner terminated by the Board, the Option Plan will in all events
terminate on February 25, 2006. Any options outstanding at the time of such
termination will remain in force in accordance with the provisions of the
instruments evidencing such grants.
NEW OPTION PLAN BENEFITS. As of March 31, 1997 options covering 3,581,591
shares were outstanding under the Option Plan, 1,592,259 shares remained
available for future option grants, and 326,150 shares had been issued under the
Option Plan. The expiration dates for all such options range from February 2003
to March 2007. In addition to the options granted under the Option Plan, in 1996
the Company granted six non-statutory options to purchase an aggregate of
939,880 shares of Common Stock. These non-statutory options are reflected in the
number of options granted to executive officers as a group below.
10
<PAGE>
Except as set forth above under the caption "Automatic Option Grant
Program," grants to be made under the Option Plan in the future are at the
discretion of the Committee and are not determinable at this time. The following
table shows all option grants during the fiscal year ended December 31, 1996 and
through March 31, 1997, to the indicated individuals, all current executive
officers as a group, all current directors who are not executive officers as a
group, and all employees (including all current officers who are not executive
officers) as a group, respectively:
<TABLE>
<CAPTION>
NUMBER OF
NAME OPTION SHARES
- ------------------------------------------------------------------------------- -------------
<S> <C>
Wesley D. Sterman, M.D......................................................... 0
Richard B. Brewer.............................................................. 560,000
David B. Singer................................................................ 429,000
Bradford J. Shafer............................................................. 350,000
Casey M. Tansey................................................................ 0
Steven E. Johnson.............................................................. 0
Robert J. Chin, Ph.D........................................................... 0
Frank M. Fischer............................................................... 0
Robert V. Gunderson, Jr........................................................ 0
Joseph S. Lacob................................................................ 0
John H. Stevens, M.D........................................................... 0
Petri T. Vainio, M.D., Ph.D.................................................... 0
Steven C. Wheelwright, Ph.D.................................................... 0
All Executive Officers as a group (10 persons)................................. 1,694,000
All Directors who are not employees (6 persons)................................ 0
All Employees (including officers who are not executive officers, 332
persons)..................................................................... 3,217,855
</TABLE>
FEDERAL INCOME TAX CONSEQUENCES OF OPTIONS GRANTED UNDER THE OPTION PLAN
Options granted under the Option Plan may be either Incentive Options that
satisfy the requirements of Section 422 of the Code or non-statutory options
that are not intended to meet such requirements. The Federal income tax
treatment for the two types of options differs as follows:
INCENTIVE STOCK OPTIONS. No taxable income is recognized by the optionee at
the time of the option grant, and no taxable income is generally recognized at
the time the option is exercised. However, the excess of the fair market value
of the purchased shares on the exercise date over the exercise price paid for
the shares generally is includable in alternative minimum taxable income. The
optionee will recognize taxable income in the year in which the purchased shares
are sold or otherwise made the subject of disposition.
For Federal tax purposes, dispositions are divided into two categories: (i)
qualifying and (ii) disqualifying. The optionee will make a qualifying
disposition of the purchased shares if the sale or other disposition of such
shares is made after the optionee has held the shares for more than two years
after the grant date of the option and more than one year after the exercise
date. If the optionee fails to satisfy either of these two holding periods prior
to the sale or other disposition of the purchased shares, then a disqualifying
disposition will result.
Upon a qualifying disposition of the shares, the optionee will recognize
long-term capital gain in an amount equal to the excess of (i) the amount
realized upon the sale or other disposition of the purchased shares over (ii)
the exercise price paid for such shares. If there is a disqualifying disposition
of the shares, then the excess of (i) the fair market value of those shares on
the date the option was exercised over (ii) the exercise price paid for the
shares will be taxable as ordinary income. Any additional gain recognized upon
the disposition will be a capital gain.
11
<PAGE>
If the optionee makes a disqualifying disposition of the purchased shares,
then the Company will be entitled to an income tax deduction for the taxable
year in which such disposition occurs equal to the excess of (i) the fair market
value of such shares on the date the option was exercised over (ii) the exercise
price paid for the shares. In no other instance will the Company be allowed a
deduction with respect to the optionee's disposition of the purchased shares.
The Company anticipates that any compensation deemed paid by the Company upon
one or more disqualifying dispositions of Incentive Option shares by the
Company's executive officers will remain deductible by the Company and will not
have to be taken into account for purposes of the $1 million limitation per
covered individual on the deductibility of the compensation paid to certain
executive officers of the Company.
NON-STATUTORY OPTIONS. No taxable income is recognized by an optionee upon
the grant of a non-statutory option.
The optionee will in general recognize ordinary income in the year in which
the option is exercised equal to the excess of the fair market value of the
purchased shares on the exercise date over the exercise price paid for the
shares, and the optionee will be required to satisfy the tax withholding
requirements applicable to such income.
Special provisions of the Code apply to the acquisition of Common Stock
under a non-statutory option if the purchased shares are subject to repurchase
by the Company. These special provisions may be summarized as follows:
(i) If the shares acquired upon exercise of the non-statutory option are
subject to repurchase by the Company at the original exercise price in the
event of the optionee's termination of service prior to vesting in such
shares, the optionee will not recognize any taxable income at the time of
exercise but will have to report as ordinary income, as and when the
Company's repurchase right lapses, an amount equal to the excess of (a) the
fair market value of the shares on the date such repurchase right lapses
with respect to such shares over (b) the exercise price paid for the shares.
(ii) The optionee may, however, elect under Section 83(b) of the Code to
include as ordinary income in the year of exercise of the non-statutory
option an amount equal to the excess of (a) the fair market value of the
purchased shares on the exercise date (determined as if the shares were not
subject to the Company's repurchase right) over (b) the exercise price paid
for such shares. If the Section 83(b) election is made, the optionee will
not recognize any additional income as and when the repurchase right lapses.
The Company will be entitled to a business expense deduction equal to the
amount of ordinary income recognized by the optionee with respect to the
exercised non-statutory option. The deduction will in general be allowed for the
taxable year of the Company in which such ordinary income is recognized by the
optionee. The Company anticipates that the compensation deemed paid by the
Company upon the exercise of non-statutory options with exercise prices equal to
the fair market value of the option shares on the grant date will remain
deductible by the Company and will not have to be taken into account for
purposes of the $1 million limitation per covered individual on the
deductibility of the compensation paid to certain executive officers of the
Company.
STOCK APPRECIATION RIGHTS. An optionee who is granted a stock appreciation
right will recognize ordinary income in the year of exercise equal to the amount
of the appreciation distribution. The Company will be entitled to a business
expense deduction equal to the appreciation distribution for the taxable year of
the Company in which the ordinary income is recognized by the optionee.
RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board of Directors recommends that the stockholders vote FOR the
amendment to the 1996 Stock Option Plan.
12
<PAGE>
PROPOSAL 3
AMENDMENT TO THE EMPLOYEE STOCK PURCHASE PLAN
The Employee Stock Purchase Plan (the "Purchase Plan") was adopted by the
Board of Directors on February 26, 1996 and approved by the stockholders on
April 10, 1996. The Purchase Plan was amended on October 21, 1996 to (a) provide
for the commencement of twenty-four month concurrent offering periods with
purchases generally occurring every six months; (b) permit participants to
contribute a maximum of 15% of eligible compensation, and (c) expand eligible
compensation to include, in addition to base salary, bonuses, commissions and
all other cash compensation. The stockholders are being asked to approve the
amendment to the Purchase Plan. In the absence of contrary instructions, the
proxy holders intend to vote all proxies received by them FOR the amendment to
the Purchase Plan. The Purchase Plan, and the right of participants to make
purchases thereunder, is intended to meet the requirements of an "employee stock
purchase plan" as defined in Section 423 of the Code. If the amendment to the
Purchase Plan is not approved by the stockholders, the Purchase Plan will
continue in effect in accordance with its current terms.
SUMMARY OF PURCHASE PLAN
The following summary of certain Purchase Plan provisions is qualified, in
its entirety, by reference to the Purchase Plan. Copies of the Purchase Plan
document may be obtained by a stockholder upon written request to the Secretary
of the Company at the executive offices in Redwood City, California.
PURPOSE. The purpose of the Purchase Plan is to provide employees of the
Company and designated parent or subsidiary corporations (collectively,
"Participating Companies") an opportunity to participate in the ownership of the
Company by purchasing Common Stock through payroll deductions. The Company and
its subsidiaries, Heartport Research and Training Center, Inc. and UBTL, Inc.,
are the only Participating Companies in the Purchase Plan.
The Purchase Plan is intended to benefit the Company as well as its
stockholders and employees. The Purchase Plan gives employees an opportunity to
purchase shares of Common Stock at a favorable price. The Company believes that
the stockholders will correspondingly benefit from the increased interest on the
part of participating employees in the profitability of the Company. Finally,
the Company will benefit from the periodic investments of equity capital
provided by participants in the Purchase Plan.
ADMINISTRATION. The Purchase Plan is administered by the Compensation
Committee of the Board (the "Committee"). All costs and expenses incurred in
plan administration will be paid by the Company without charge to participants.
All cash proceeds received by the Company from payroll deductions under the
Purchase Plan shall be credited to a non-interest bearing book account.
SHARES AND TERMS. The stock issuable under the Purchase Plan is the
Company's authorized but unissued or reacquired Common Stock. The maximum number
of shares of Common Stock that may be issued in the aggregate under the Purchase
Plan is 240,000, adjusted as described in the "Adjustments" section of this
description. Common Stock subject to a terminated purchase right shall be
available for purchase pursuant to purchase rights subsequently granted. As of
March 31, 1997, 18,699 shares have been issued under the Purchase Plan and
221,301 shares remain available for future issuance.
ADJUSTMENTS. If any change in the Common Stock occurs (through
recapitalization, stock dividend, stock split, combination of shares, exchange
of shares, or other change affecting the outstanding Common Stock as a class
without the Company's receipt of consideration), appropriate adjustments shall
be made by the Company to the class and maximum number of shares subject to the
Purchase Plan, to the class and maximum number of shares purchasable by each
participant on any one purchase date, and the class and number of shares and
purchase price per share subject to outstanding purchase rights in order to
prevent the dilution or enlargement of benefits thereunder.
13
<PAGE>
ELIGIBILITY. Generally, any individual who is customarily employed by a
Participating Company more than 20 hours per week and for more than five months
per calendar year is eligible to participate in the Purchase Plan. Approximately
331 employees (including 9 officers) were eligible to participate in the
Purchase Plan as of March 31, 1997.
OFFERING PERIODS. The Purchase Plan is implemented by a series of offering
periods that generally have a duration of twenty-four months and may be
concurrent or sequential, in the discretion of the Committee. The initial
offering period under the Purchase Plan, implemented prior to the October 21,
1996 amendment of the Purchase Plan, began on the date of execution of the
underwriting agreement in connection with the Company's initial public offering
and ended on October 31, 1996. As a result of the amendment that is the subject
of this Proposal No. 3, offering periods may now be concurrent and successive
and, accordingly, a new offering period will commence every six months and run
concurrently with each prior offering period. The Committee in its discretion
may vary the beginning date and ending date of the offering periods prior to
their commencement, provided no offering period shall exceed twenty-four months
in length. The first offering period under the amended plan began on November 1,
1996 and will end on the last business day of October 1998, assuming approval of
the amendment that is the subject of this Proposal No. 3. The next offering
period will commence on June 1, 1997 and will end on the last business day in
April 1999, unless terminated earlier. The purchase periods for the offering
period that began on November 1, 1996 will end on May 30, 1997, October 31,
1997, April 30, 1998, and October 30, 1998. The purchase periods under the
offering period that will begin on June 1, 1997 will end on October 31, 1997,
April 30, 1998, October 30, 1998, and April 30, 1999. The Committee has complete
discretion to vary the beginning and ending date of an offering period or
purchase period prior to the commencement of any purchase period. Should the
stockholders not approve the amendment that is the subject of this Proposal No.
3, then the November 1, 1996 offering period will end on May 31, 1997 and each
subsequent offering period will have a maximum duration of six months.
A participant will have a separate purchase right for each offering period
in which he or she participates. The purchase right will be granted on the first
day of the offering period and will be automatically exercised in successive
installments on the last day of each purchase period within the offering period.
PURCHASE PRICE. The purchase price per share under the Purchase Plan is 85%
of the lower of (i) the fair market value of a share of Common Stock on the
first day of the applicable offering period or (ii) the fair market value of a
share of Common Stock on the purchase date. Generally, the fair market value of
the Common Stock on a given date is the closing sale price of the Common Stock,
as reported on the Nasdaq National Market. The market value of the Common Stock
as reported on the Nasdaq National Market as of March 31, 1997, was $24.50 per
share.
LIMITATIONS. The Purchase Plan imposes certain limitations upon a
participant's rights to acquire Common Stock, including the following:
(1) No purchase right shall be granted to any person who immediately
thereafter would own, directly or indirectly, stock or hold outstanding
options or rights to purchase stock possessing five percent (5%) or more of
the total combined voting power or value of all classes of stock of the
Company or any of its parent or subsidiary corporations.
(2) In no event shall a participant be permitted to purchase more than
1,000 shares on any one purchase date.
(3) The right to purchase Common Stock under the Purchase Plan (or any
other employee stock purchase plan that the Company or any of its
subsidiaries may establish) in an offering intended to qualify under Section
423 of the Code may not accrue at a rate that exceeds $25,000 in fair market
value of such Common Stock (determined at the time such purchase right is
granted) for any calendar year in which such purchase right is outstanding.
14
<PAGE>
The purchase right shall be exercisable only by the participant during the
participant's lifetime and shall not be assignable or transferable by the
participant.
PAYMENT OF PURCHASE PRICE; PAYROLL DEDUCTIONS. Payment for shares by
participants shall be by accumulation of after-tax payroll deductions during the
purchase period. The deductions may not exceed 15% of a participant's cash
compensation paid during a purchase period. Cash compensation for this purpose
will include elective contributions that are not includable in income under Code
Sections 125 or 401(k) and all bonuses, overtime, commissions, and other amounts
to the extent paid in cash. Prior to amendment of the Purchase Plan, the maximum
deduction was limited to 10% of base salary.
The participant will receive a purchase right for each offering period in
which he or she participates to purchase up to the number of shares of Common
Stock determined by dividing such participant's payroll deductions accumulated
prior to the purchase date by the applicable purchase price (subject to the
"Limitations" section). No fractional shares shall be purchased. Any payroll
deductions accumulated in a participant's account that are not sufficient to
purchase a full share will be retained in the participant's account for the
subsequent purchase period. No interest shall accrue on the payroll deductions
of a participant in the Purchase Plan.
TERMINATION AND CHANGE TO PAYROLL DEDUCTIONS. A purchase right shall
terminate at the end of the offering period or earlier if (i) the participant
terminates employment, in which case any payroll deductions that the participant
may have made with respect to a terminated purchase right will be refunded, or
(ii) the participant elects to withdraw from the Purchase Plan. Any payroll
deductions that the participant may have made with respect to a terminated
purchase right under clause (ii) will be refunded unless the participant elects
to have the funds applied to the purchase of shares on the next purchase date.
Unless a participant has irrevocably elected otherwise, he or she may decrease
his or her deductions once during a purchase period.
AMENDMENT AND TERMINATION. The Purchase Plan shall continue in effect until
the earlier of (i) the last business day in October, 2006, (ii) the date on
which all shares available for issuance under the Purchase Plan shall have been
issued or (iii) a Corporate Transaction, unless the Purchase Plan is earlier
terminated by the Board in its discretion.
The Board may at any time alter, amend, suspend or discontinue the Purchase
Plan, provided that, without the approval of the stockholders, no such action
may (i) alter the purchase price formula so as to reduce the purchase price
payable for shares under the Purchase Plan, (ii) materially increase the number
of shares issuable under the Purchase Plan or the maximum number of shares
purchasable per participant, or (iii) materially increase the benefits accruing
to participants under the Purchase Plan or materially modify the eligibility
requirements.
In addition, the Company has specifically reserved the right, exercisable in
the sole discretion of the Board, to terminate the Purchase Plan immediately
following any six month purchase period. If such right is exercised by the
Board, then the Purchase Plan will terminate in its entirety and no further
purchase rights will be granted or exercised, and no further payroll deductions
shall thereafter be collected under the Purchase Plan.
CORPORATE TRANSACTION. In the event of (i) a merger or consolidation in
which securities possessing more than fifty percent (50%) of the total combined
voting power of the Company's outstanding securities are transferred to a person
or persons different from the persons holding those securities immediately prior
to such transaction or (ii) the sale, transfer or other disposition of all or
substantially all of the assets of the Company in complete liquidation or
dissolution of the Company (a "Corporate Transaction"), each purchase right
under the Purchase Plan will automatically be exercised immediately before
consummation of the Corporate Transaction as if such date were the last purchase
date of the offering period. The purchase price per share shall be equal to
eighty-five percent (85%) of the lower of the fair market value per share of
Common Stock on the start date of the offering period or the fair market
15
<PAGE>
value per share of Common Stock immediately prior to the effective date of such
Corporate Transaction. Any payroll deductions not applied to such purchase shall
be promptly refunded to the participant.
The grant of purchase rights under the Purchase Plan will in no way affect
the right of the Company to adjust, reclassify, reorganize, or otherwise change
its capital or business structure or to merge, consolidate, dissolve, liquidate
or sell or transfer all or any part of its business or assets.
PRORATION OF PURCHASE RIGHTS. If the total number of shares of Common Stock
for which purchase rights are to be granted on any date exceeds the number of
shares then remaining available under the Purchase Plan, the Committee shall
make a pro rata allocation of the shares remaining.
FEDERAL INCOME TAX CONSEQUENCES. The following is a general description of
certain federal income tax consequences of the Purchase Plan. This description
does not purport to be complete.
The Purchase Plan is intended to qualify as an "employee stock purchase
plan" under Section 423 of the Code. Under a plan which so qualifies, no taxable
income will be reportable by a participant, and no deductions will be allowable
to the Company, by reason of the grant or exercise of the purchase rights issued
thereunder. A participant will, however, recognize taxable income in the year in
which the purchased shares are sold or otherwise made the subject of
disposition.
A sale or other disposition of the purchased shares will be a disqualifying
disposition if made before the later of two years after the start of the
offering period in which such shares were acquired or one year after the shares
are purchased. If the participant makes a disqualifying disposition of the
purchased shares, then the Company will be entitled to an income tax deduction
for the taxable year in which such disposition occurs, equal to the amount by
which the fair market value of such shares on the date of purchase exceeded the
purchase price, and such amount will be taxable as ordinary income to the
participant who will be required to satisfy the employment and income tax
withholding requirements applicable to such income. In no other instance will
the Company be allowed a deduction with respect to the participant's disposition
of the purchased shares.
Any additional gain or loss recognized upon the disposition of the shares
will be a capital gain, which will be long-term if the shares have been held for
more than one year following the date of purchase under the Purchase Plan.
The foregoing is only a summary of the federal income taxation consequences
to the participant and the Company with respect to the shares purchased under
the Purchase Plan. In addition, the summary does not discuss the tax
consequences of a participant's death or under the income tax laws of any city,
state or foreign country in which the participant may reside.
NEW PURCHASE PLAN BENEFITS. Since purchase rights are subject to
discretion, including an employee's decision not to participate in the Purchase
Plan, awards under the Purchase Plan for the current fiscal year are not
determinable. However, in the purchase period that ended on October 31, 1996
each of the following executive officers purchased the following number of
shares of Common Stock at a purchase price of $17.85 per share: Mr. Brewer: 653;
Mr. Singer: 0; Mr. Shafer: 0; Mr. Tansey: 571; Mr. Johnson: 572; Dr. Chin: 478;
and all executive officers as a group (10 persons) purchased 2,642 shares. In
addition, each of the Named Officers, other than Dr. Sterman, has the right to
purchase a maximum of 1,000 shares of Common Stock at a price that will not
exceed $22.10 per share on each of the May 30, 1997, October 31, 1997, April 30,
1998, and October 30, 1998 purchase dates.
RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board of Directors recommends a vote FOR the approval of the amendment
to the Company's Employee Stock Purchase Plan.
16
<PAGE>
PROPOSAL 4
RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS
The firm of Ernst & Young LLP served as independent auditors for the Company
for the fiscal year ended December 31, 1996. The Board of Directors desires the
firm to continue in this capacity for the current fiscal year. Accordingly, a
resolution will be presented to the meeting to ratify the selection of Ernst &
Young LLP by the Board of Directors as the Company's independent auditors to
audit the accounts and records of the Company for the fiscal year ending
December 31, 1997, and to perform other appropriate services. In the event that
stockholders fail to ratify the selection of Ernst & Young LLP, the Board of
Directors would reconsider such selection. Even if the selection is ratified,
the Board of Directors in its discretion may direct the appointment of a
different independent auditing firm at any time during the year if the Board of
Directors believes that such a change would be in the best interests of the
Company and its stockholders.
A representative of Ernst & Young LLP will be present at the Annual Meeting
to respond to appropriate questions and to make a statement if such
representative desires to do so.
RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board of Directors recommends that the stockholders vote FOR the
ratification of the selection of Ernst & Young LLP to serve as the Company's
independent auditors for the fiscal year ending December 31, 1997.
17
<PAGE>
OWNERSHIP OF SECURITIES
MANAGEMENT AND DIRECTORS
The following table sets forth the beneficial ownership of Common Stock as
of December 31, 1996, by each director, each executive officer named in the
Summary Compensation Table in the "Executive Compensation" section below and all
directors and executive officers as a group. All shares are subject to the named
person's sole voting and investment power except where otherwise indicated.
<TABLE>
<CAPTION>
APPROXIMATE
SHARES PERCENTAGE
BENEFICIALLY BENEFICIALLY
NAME OWNED(#) OWNED(1)(%)
- ---------------------------------------------------------------- ----------- -------------------
<S> <C> <C>
Frank M. Fischer................................................ 218,667 *
Robert V. Gunderson, Jr......................................... 148,043 *
Joseph S. Lacob (2)............................................. 113,783 *
John H. Stevens, M.D............................................ 2,567,950 10.5
Petri T. Vainio, M.D., Ph.D..................................... 192,095 *
Steven C. Wheelwright, Ph.D..................................... 141,400 *
Wesley D. Sterman, M.D.......................................... 3,245,332 13.3
Richard B. Brewer (3)........................................... 560,653 2.3
David B. Singer (4)............................................. 45,799 *
Bradford J. Shafer.............................................. 0 *
Casey M. Tansey................................................. 328,571 1.4
Steven E. Johnson............................................... 374,972 1.5
Robert J. Chin, Ph.D. (5)....................................... 308,478 1.3
Randall S. Livingston........................................... 86,000 *
All current directors and executive officers as a group (17
persons) (6).................................................. 9,043,511 37.0
</TABLE>
- ------------------------
* Less than 1% of the outstanding shares of Common Stock.
(1) Percentage of ownership is based on 24,415,128 shares of Common Stock
outstanding on December 31, 1996. The number of shares of Common Stock
beneficially owned includes the shares issuable pursuant to stock options
that are exercisable within 60 days of December 31, 1996. Shares issuable
pursuant to stock options are deemed outstanding for computing the
percentage of the person holding such options but are not outstanding for
computing the percentage of any other person.
(2) Includes options immediately exercisable for 80,000 shares of Common Stock.
(3) Includes options immediately exercisable for 560,000 shares of Common Stock.
(4) Represents options exercisable within 60 days of December 31, 1996.
(5) Includes options immediately exercisable for 176,000 shares of Common Stock.
(6) Includes options immediately exercisable, or exercisable within 60 days of
December 31, 1996, for 866,999 shares of Common Stock.
18
<PAGE>
EXECUTIVE COMPENSATION AND RELATED INFORMATION
SUMMARY OF CASH AND CERTAIN OTHER COMPENSATION
The following table sets forth the compensation earned for services rendered
in all capacities to the Company and its subsidiaries for the two fiscal years
ended December 31, 1996 by the Company's Chief Executive Officer and each of the
Company's four other highest-paid executive officers (determined as of the end
of the last fiscal year) plus two additional executive officers and one
additional individual who would have otherwise been includible in such table on
the basis of salary and bonus earned for the 1996 fiscal year but who resigned
or terminated employment during the fiscal year (the "Named Officers").
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
COMPENSATION
AWARDS(1)
ANNUAL COMPENSATION ------------
----------------------------------------- SECURITIES ALL OTHER
OTHER ANNUAL UNDERLYING COMPENSATION
NAME AND PRINCIPAL POSITION FISCAL YEAR SALARY ($) BONUS ($) COMPENSATION ($) OPTIONS (#) ($)
- ---------------------------------------- ----------- ---------- --------- ---------------- ------------ -------------
<S> <C> <C> <C> <C> <C> <C>
Wesley D. Sterman, M.D. ................ 1996 216,033 32,405 0 0 0
President, Chief Executive Officer and 1995 196,667 13,767 0 640,000 0
Director
Richard B. Brewer ...................... 1996 175,128 26,269 0 560,000 0
Chief Operating Officer 1995 0 0 0 0 0
David B. Singer ........................ 1996 100,000 7,000 0 429,000 0
Senior Vice President, Finance and 1995 0 0 0 0 0
Chief Financial Officer
Bradford J. Shafer ..................... 1996 85,641 5,995 0 350,000 0
General Counsel and Secretary 1995 0 0 0 0 0
Casey M. Tansey ........................ 1996 175,557 26,250 0 0 0
Vice President, Sales and Marketing 1995 7,778 544 0 328,000 0
Steven E. Johnson ...................... 1996 172,796 25,919 47,613(2) 0 0
Vice President, Manufacturing 1995 155,193 10,855 488(2) 176,000 0
Robert J. Chin, Ph.D. .................. 1996 147,693 14,769 0 0 0
Vice President, Regulatory Affairs and 1995 127,452 8,922 79,712(2) 312,000 0
Quality Assurance
Randall S. Livingston .................. 1996 175,000 0 0 0 0
Former Vice President, Finance and 1995 67,083 4,696 0 280,000 0
Chief Financial Officer
</TABLE>
- ------------------------
(1) No restricted stock grants were made to the Named Officers during the fiscal
year. As of the last day of the fiscal year, Dr. Sterman held 135,436 shares
of restricted Common Stock, which were awarded on March 1, 1992, and
purchased by delivery of a promissory note on the same date. The fair market
value of the shares, as of December 31, 1996, less the amount paid by Dr.
Sterman ($0.004 per share), was $3,098,234.
(2) Represents relocation expenses.
19
<PAGE>
STOCK OPTIONS
The following table contains information concerning the stock option grants
made to each of the Named Officers for the year ended December 31, 1996:
OPTION/SAR GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
POTENTIAL REALIZABLE
INDIVIDUAL GRANTS VALUE AT ASSUMED
------------------------------------ ANNUAL RATES OF STOCK
NUMBER OF % OF TOTAL PRICE APPRECIATION FOR
SECURITIES OPTIONS GRANTED EXERCISE OR OPTION TERM(3)
UNDERLYING OPTIONS TO EMPLOYEES IN BASE PRICE EXPIRATION ----------------------
NAME GRANTED (#)(1) FISCAL YEAR ($/SH)(2) DATE 5%($) 10%($)
- -------------------------------------- ------------------ --------------- ----------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
Wesley D. Sterman, M.D................ 0 -- -- -- -- --
Richard B. Brewer..................... 400,000(4) 14.3 7.50 02/08/06 1,886,684 4,781,227
160,000(5) 5.7 7.50 02/08/06 754,674 1,912,491
David B. Singer....................... 300,000(6) 10.7 21.75 07/14/06 4,103,537 10,399,170
125,000(7) 4.5 21.75 07/14/06 1,709,807 4,332,987
4,000(8) 0.1 7.50 02/08/06 18,869 47,812
Bradford J. Shafer.................... 225,000(6) 8.0 21.75 07/14/06 3,077,653 7,799,377
125,000(7) 4.5 21.75 07/14/06 1,709,807 4,332,987
Casey M. Tansey....................... 0 -- -- -- -- --
Steven E. Johnson..................... 0 -- -- -- -- --
Robert J. Chin, Ph.D.................. 0 -- -- -- -- --
Randall S. Livingston................. 0 -- -- -- -- --
</TABLE>
- ------------------------
(1) The option shares will vest immediately upon an acquisition of the Company
by merger or asset sale unless assumed or replaced by the acquiring entity.
Each option has a maximum term of ten years, subject to earlier termination
in the event of the optionee's cessation of employment with the Company. For
additional information concerning the terms of the options listed in the
table, see "Proposal 2--Amendment to the 1996 Stock Option Plan,"
"Employment Agreements," and "Change in Control Arrangements."
(2) The exercise price may be paid in cash, in shares of Common Stock valued at
fair market value on the exercise date, or through a cashless exercise
procedure involving a same-day sale of the purchased shares.
(3) The 5% and 10% assumed annual rates of compounded stock price appreciation
are mandated by rules of the Securities and Exchange Commission. There can
be no assurance provided to any executive officer or any other holder of the
Company's securities that the actual stock price appreciation over the ten
year option term will be at the assumed 5% and 10% levels or at any other
defined level. Unless the market price of the Common Stock appreciates over
the option term, no value will be realized from the option grants made to
the executive officers.
(4) With respect to the shares purchasable under such grants, the optionee vests
as to 20% of the option shares upon completion of one year of service and
the balance in a series of equal monthly installments over the next
forty-eight months of service.
(5) With respect to the shares purchasable under such grants, the optionee vests
in 60 equal monthly installments beginning from the fifth anniversary of
date of hire.
20
<PAGE>
(6) A portion of these options were granted as non-statutory options outside of
the Company's 1996 Stock Option Plan on terms substantially similar to the
terms of options granted under such plan. The options become exercisable as
to 20% of the option shares upon completion of one year of service and the
balance in a series of equal monthly installments over the next forty-eight
months of service.
(7) A portion of these options were granted as non-statutory options outside of
the Company's 1996 Stock Option Plan on terms substantially similar to the
terms of options granted under such plan. The options become exercisable in
60 equal monthly installments beginning from the fifth anniversary of date
of hire.
(8) The option becomes exercisable in 60 equal monthly installments beginning
from the grant date.
OPTION EXERCISES AND HOLDINGS
The following table sets forth information concerning option holdings for
the year ended December 31, 1996, with respect to each of the Named Officers. No
options were exercised by the Named Officers during the 1996 fiscal year. No
stock appreciation rights were exercised during such year or were outstanding at
the end of that year.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS
OPTIONS AT FY-END(#) AT FY-END(1)($)
----------------------------- -----------------------------
NAME EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ------------------------------------------------------------ ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Wesley D. Sterman, M.D...................................... 0 0 0 0
Richard B. Brewer........................................... 560,000(2) 0 8,612,800 0
David B. Singer............................................. 45,666 383,334 61,093 480,677
Bradford J. Shafer.......................................... 0 350,000 0 395,500
Casey M. Tansey............................................. 0 0 0 0
Steven E. Johnson........................................... 0 0 0 0
Robert J. Chin, Ph.D........................................ 176,000(2) 0 3,960,880 0
Randall S. Livingston....................................... 0 0 0 0
</TABLE>
- ------------------------
(1) Based on the fair market value of the Common Stock at year-end ($22.88 per
share) less the exercise price payable for such shares.
(2) The options are immediately exercisable, but any shares purchased under the
options will be subject to a repurchase option in favor of the Company at
the original exercise price per share upon the optionee's cessation of
service. The repurchase right has not lapsed as to any of the shares as of
December 31, 1996. The holder of purchased shares, whether or not subject to
the Company's repurchase option, is entitled to vote all such shares.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Compensation Committee of the Company's Board of Directors was formed in
February, 1996, and the members of the Compensation Committee are Dr.
Wheelwright, Mr. Fischer, and Dr. Vainio. None of these individuals was at any
time during the year ended December 31, 1996, or at any other time, an officer
or employee of the Company. No member of the Compensation Committee of the
Company serves as a member of the board of directors or compensation committee
of any entity that has one or more executive officers serving as a member of the
Company's Board of Directors or Compensation Committee.
21
<PAGE>
EMPLOYMENT AGREEMENTS
The Company presently has employment agreements with Mr. Brewer, Mr. Singer,
and Dr. Siegel as described below.
On February 8, 1996, the Company entered into an employment agreement with
Richard B. Brewer, the Company's Chief Operating Officer, pursuant to which his
salary was set at $200,000 per annum and the Company agreed to grant him options
to purchase 400,000 shares of Common Stock vesting over five years from his
employment date and additional options to purchase 160,000 shares of Common
Stock vesting over five years beginning on his fifth anniversary of employment.
The agreement provides for acceleration of vesting of his option shares as if
his service continued for an additional twelve months should there be (1) an
involuntary termination of his employment without cause during the twelve month
period following certain changes in control involving the Company or the three
month period preceding the change in control if his termination were directly or
indirectly directed by the acquiring entity or (2) a change in his reporting
relationship such that he no longer reports to the Company's Chief Executive
Officer.
On May 29, 1996, the Company entered into an employment agreement with David
B. Singer, the Company's Senior Vice President, Finance and Chief Financial
Officer pursuant to which his salary was set at $200,000 per annum and the
Company agreed to grant him options to purchase 300,000 shares of Common Stock
vesting over five years from his employment date and additional options to
purchase 125,000 shares of Common Stock vesting over five years beginning on his
fifth anniversary of employment. The agreement provides for nine months of
salary continuation and vesting of his stock options as if his service continued
for an additional nine months should there be an involuntary termination of his
employment without cause other than in connection with a change in control. The
agreement also provides for acceleration of his option shares as if his service
continued for an additional thirty months should there be an involuntary
termination of his employment without cause during the eighteen month period
following certain changes in control involving the Company or the three month
period preceding the change in control if his termination were directly or
indirectly directed by the acquiring entity.
On September 18, 1996, the Company entered into an employment agreement with
Dr. Lawrence C. Siegel, the Company's Vice President of Clinical Affairs,
pursuant to which his salary was set at $200,000 per annum; the Company agreed
to grant him options to purchase 180,000 shares of Common Stock vesting over
five years from his employment date and additional options to purchase 120,000
shares of Common Stock vesting over five years beginning on his fifth
anniversary of employment; and the Company agreed to assist Dr. Siegel in
continuing or substituting a real property loan obtained by Dr. Siegel from
Stanford University. The agreement also provides for severance payments of
twelve months of salary and vesting of his stock options as if his service
continued for an additional twelve months should there be an involuntary
termination of his employment without cause.
CHANGE IN CONTROL ARRANGEMENTS
Each executive officer of the Company is eligible to participate in the
Company's Change in Control Severance Plan (the "Severance Plan"). To the extent
that any of the executive officers has other severance arrangements with the
Company, such executive officers shall be paid the benefits provided under the
Severance Plan or their existing severance arrangements, whichever provides a
greater benefit. Under the Severance Plan, in the event that an officer is
involuntarily terminated within twenty-four months following certain changes in
control, such officer shall receive severance benefits equal to twenty-four
months of salary plus a bonus equal to 200% of such officer's target bonus.
On March 12, 1997, the Compensation Committee of the Company's Board of
Directors (the "Committee") agreed to amend outstanding options, including
options held by Mr. Brewer, granted prior to the date of the initial public
offering to provide that the exercisability of each such option will accelerate
upon a Corporate Transaction unless the option is assumed in connection with the
Corporate Transaction.
22
<PAGE>
The Committee also amended unvested shares purchased or purchasable under
options granted prior to the initial public offering, including shares held by
Messrs. Sterman, Chin, Johnson, Gifford and Tansey, to provide that the vesting
of the shares will accelerate upon a Corporate Transaction unless the Company's
repurchase right is assigned in connection with the Corporate Transaction. In
addition, upon an involuntary termination of the optionee's service within
twelve months following a Corporate Transaction, the exercisability of the
option (or the vesting of the shares) will accelerate for a number of shares as
if the optionee's service continued for an additional twelve months following
the involuntary termination, unless otherwise provided in the individual's
employment agreement.
The Committee has the authority under the 1996 Stock Option Plan to provide
for the acceleration of vesting of the shares of Common Stock subject to the
outstanding options held by the Chief Executive Officer and the Company's other
executive officers under that Plan at any time, including in connection with
Corporate Transactions or a hostile take-over of the Company, whether effected
through a successful tender offer for more than 50% of the Company's outstanding
Common Stock or through a change in the majority of the Board as a result of one
or more contested elections for Board membership, which may or may not be
conditioned on their employment being terminated (whether involuntarily or
through a forced resignation).
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires
the Company's directors, executive officers and persons who own more than ten
percent of a registered class of the Company's equity securities, to file with
the Securities and Exchange Commission (the "SEC") initial reports of ownership
and reports of changes in ownership of Common Stock and other equity securities
of the Company. Officers, directors and greater-than-ten-percent beneficial
owners are required by SEC regulations to furnish the Company with copies of all
Section 16(a) reports they file.
Based solely upon review of the copies of such reports furnished to the
Company and written representations that no other reports were required, the
Company believes that there was compliance for the fiscal year ended December
31, 1996, with all Section 16(a) filing requirements applicable to the Company's
officers, directors and greater-than-ten-percent beneficial owners.
23
<PAGE>
REPORT OF THE COMPENSATION COMMITTEE
The Compensation Committee of the Company's Board of Directors (the
"Committee") is responsible for establishing policies and programs for
compensating Heartport's executive officers. Each year, the Committee determines
the base salary payable to the Chief Executive Officer ("CEO") and all other
executive officers and approves the incentive bonus program for the CEO and
other executive officers. In addition, the Committee administers the Company's
1996 Stock Option Plan and Employee Stock Purchase Plan. The Committee has the
exclusive authority to grant stock options to the Company's officers. For fiscal
1996, the Committee considered both qualitative and quantitative factors in
determining executive officer compensation levels, including
commercially-prepared surveys of comparable companies and input from outside
compensation consultants.
COMPENSATION POLICY AND PHILOSOPHY
The Committee's policy is to develop executive compensation packages that
attract, retain and motivate highly effective executives. Compensation programs
are designed to reward the achievement of both short-term and long-term
objectives of the Company and to align the executives' interests with those of
the Company's stockholders. It is the Committee's objective to have a
substantial portion of each officer's compensation contingent upon the Company's
performance, as well as upon his or her own level of performance. Accordingly,
each executive officer's compensation package consists of three major
components: (i) base salary, (ii) annual cash incentive compensation, and (iii)
long-term stock-based incentive awards.
BASE SALARY
The base salary for each executive officer is set by reviewing the pay
practices of companies that compete with the Company for executive talent, and
by evaluating each individual's performance and contribution.
ANNUAL CASH INCENTIVE COMPENSATION
Each executive officer has an annual bonus target. The total bonus pool for
executive officers is determined based on the Company's achievement of goals
established at the start of the fiscal year. For fiscal 1996, the
corporate-level goals were primarily related to the rapid commercialization of
the Company's products and to continued product innovation. For fiscal 1997,
these goals also include revenue growth. The Company exceeded its performance
targets in 1996. Actual bonuses paid reflect both the achievement of corporate
goals and the individual's specific functional objectives, with greater weight
being given to the achievement of corporate goals. Actual bonuses for the Named
Officers are listed in the Summary Compensation Table.
LONG-TERM STOCK-BASED INCENTIVE AWARDS
During fiscal 1996, the Committee made significant option grants to Messrs.
Brewer, Singer, Siegel, and Shafer in connection with recruiting such
individuals to work for the Company, but made no option grants to Dr. Sterman
because a significant stock grant was made to him in fiscal 1995. Generally, a
significant grant is made in the year that an executive officer commences
employment. The size of each grant is set at a level that the Committee deems
appropriate to create a meaningful opportunity for stock ownership based upon
the individual's position and responsibilities with the Company.
Each grant allows the officer to acquire shares of Common Stock at a fixed
price per share (the market price on the grant date) over a specified period of
time. In general, two options were granted to the executive officers hired in
1996: (i) an option which vests in periodic installments over the individual's
first five years of employment, and (ii) an option which vests in periodic
installments over the individual's sixth through tenth years of employment. The
vesting schedules are designed to encourage the executives to
24
<PAGE>
remain with the Company and to focus on longer-term results. An option will
provide a return to the executive officer only if he or she remains in the
Company's employ, and then only if the market price of Common Stock appreciates
over the option term.
CEO COMPENSATION
The annual base salary for Dr. Sterman, the Company's President and CEO, was
established by the Committee in May, 1996. To determine Dr. Sterman's 1996 base
salary, the Committee evaluated the achievement of the Company's goals and Dr.
Sterman's performance of his duties over the past twelve months, and considered
the base salaries paid to chief executive officers in comparable companies. Dr.
Sterman received an incentive bonus determined on the same basis as the
incentive bonuses for other executive officers. Such compensation is entirely
dependent on corporate and individual performance and is not guaranteed.
TAX LIMITATION
As a result of Federal tax legislation enacted in 1993, a publicly-held
company such as the Company is not allowed a Federal income tax deduction for
compensation paid to certain executive officers to the extent that compensation
exceeds $1 million per officer in any year. This limitation is applicable to the
Company beginning in 1996. The stockholders approved the Company's 1996 Stock
Option Plan (the "1996 Plan"), which includes a provision that limits the
maximum number of shares of Common Stock for which any one participant may be
granted stock options per calendar year. Accordingly, any compensation deemed
paid to an executive officer when he or she exercises an option under the 1996
Plan with an exercise price equal to the fair market value of the option shares
on the grant date generally will qualify as performance-based compensation that
will not be subject to the $1 million limitation. Since it is not expected that
the cash compensation to be paid to the Company's executive officers for the
1997 fiscal year will exceed the $1 million limit per officer, the Committee
will defer any decision on whether to limit the dollar amount of the cash
compensation payable to the Company's executive officers to the $1 million cap.
Compensation Committee
Frank M. Fischer
Petri T. Vainio, M.D., Ph.D.
Steven C. Wheelwright, Ph.D.
25
<PAGE>
STOCK PERFORMANCE GRAPH
The graph set forth below compares the cumulative total stockholder return
on the Company's Common Stock between April 25, 1996 (the date the Company's
initial public offering commenced) and February 28, 1997 with the cumulative
total return of (i) the CRSP Total Return Index for the Nasdaq Stock Market
(U.S. Companies) (the "Nasdaq Stock Market-U.S. Index") and (ii) the Hambrecht
and Quist Healthcare Index (the "H&Q Healthcare Index"), over the same period.
This graph assumes the investment of $100.00 on April 25, 1996 in the Company's
Common Stock, the Nasdaq Stock Market-U.S. Index and the H&Q Healthcare Index,
and assumes the reinvestment of dividends, if any.
The comparisons shown in the graph below are based upon historical data. The
Company cautions that the stock price performance shown in the graph below is
not indicative of, nor intended to forecast, the potential future performance of
the Company's Common Stock. Information used in the graph was obtained from
Hambrecht & Quist LLC, a source believed to be reliable, but the Company is not
responsible for any errors or omissions in such information.
COMPARISON OF CUMULATIVE TOTAL RETURN AMONG HEARTPORT, INC.,
THE NASDAQ STOCK MARKET-U.S. INDEX, AND THE H&Q HEALTHCARE INDEX
EDGAR REPRESENTATION OF DATA POINTS USED IN PRINTED GRAPHIC
<TABLE>
<CAPTION>
HEARTPORT, INC. NASDAQ STOCK MARKET - U.S. H&Q HEALTHCARE
<S> <C> <C> <C>
04/25/96 100.00 100.00 100.00
Jun-96 144.05 100.43 95.76
Sep-96 123.81 104.01 103.77
Dec-96 108.95 109.12 103.08
Feb-97 141.10 110.48 109.83
</TABLE>
Notwithstanding anything to the contrary set forth in any of the Company's
previous or future filings under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, that might incorporate this Proxy
Statement or future filings made by the Company under those statutes, the
Compensation Committee Report and Stock Performance Graph shall not be deemed
filed with the Securities and Exchange Commission and shall not be deemed
incorporated by reference into any of those prior filings or into any future
filings made by the Company under those statutes.
26
<PAGE>
CERTAIN TRANSACTIONS
TRANSACTIONS WITH DIRECTORS
The Company's directors were granted the following options to purchase
shares of Common Stock in April, 1995, at an exercise price of $0.375 per share:
Dr. Wesley D. Sterman and Dr. John H. Stevens were granted options to purchase
640,000 shares and 192,000 shares, respectively. Both options are immediately
exercisable and vest monthly over a five year period beginning from the fifth
anniversary of the date of hire or the date the individual became a director, as
applicable. Each of the Company's outside directors was granted options to
purchase 80,000 shares, which vest monthly over five years from the date of
grant or from April 1, 1996. Each director except Joseph S. Lacob has exercised
in full his respective option grant. See "Executive Compensation and Related
Information" for a discussion of options granted to directors and executive
officers. All of the foregoing options granted to the directors are immediately
exercisable. The shares purchasable thereunder are subject to a repurchase
option in favor of the Company at the original exercise price paid per share
upon the director's cessation of service prior to vesting in such shares. A
director who has exercised such option and has purchased such shares, whether or
not subject to the Company's repurchase option, is entitled to vote all such
shares.
Dr. Stevens received $87,586 for consulting services to the Company in 1995
and $329,142 for reimbursement of expenses and for services to the Company in
1996. On September 1, 1995, the Company loaned Dr. Stevens $72,000 to purchase
192,000 shares of Common Stock pursuant to the exercise of options, and on March
1, 1994, the Company loaned Dr. Stevens $1,250 to purchase 20,000 shares of
Common Stock. The loans are full recourse, bear interest at the rate of 6.18%
and 6.0% per annum, respectively, are due March 1, 2002 and March 1, 1999,
respectively, and are secured by the shares of Common Stock purchased with the
proceeds of the loans. Dr. Stevens participates in the Company's clinical
affairs, product design and development, physician training, and a variety of
other matters. Dr. Stevens is one of the named inventors on many of the
Company's patents and patent applications and is a member of a surgical team
that has performed many Port-Access clinical procedures. The Company also
forgave an outstanding promissory note issued by Dr. Stevens in the amount of
$50,000 plus accrued interest in the amount of $1,654 on February 9, 1996.
INDEMNIFICATION
The Company's Certificate of Incorporation limits the liability of its
directors for monetary damages arising from a breach of their fiduciary duty as
directors, except to the extent otherwise required by the Delaware General
Corporation Law. Such limitation of liability does not affect the availability
of equitable remedies such as injunctive relief or rescission.
The Company's Bylaws provide that the Company shall indemnify its directors
and officers to the fullest extent permitted by Delaware law, including in
circumstances in which indemnification is otherwise discretionary under Delaware
law. The Company has also entered into indemnification agreements with its
officers and directors containing provisions that may require the Company, among
other things, to indemnify such officers and directors against certain
liabilities that may arise by reason of their status or service as directors or
officers (other than liabilities arising from willful misconduct of a culpable
nature), to advance their expenses incurred as a result of any proceeding
against them as to which they could be indemnified, and to obtain directors' and
officers' insurance if available on reasonable terms.
LOANS TO EMPLOYEES
In connection with the acquisition of shares of Common Stock from the
Company pursuant to the exercise of options previously granted to such
individuals, the Company on September 1, 1995, extended loans to certain of its
executive officers. Each of the loans is full recourse and is secured by the
shares of Common Stock purchased with the proceeds of the loans. In addition,
loans were extended on other dates
27
<PAGE>
for stock purchases and relocation expenses. The following table sets forth
information with respect to loans extended to the officers by the Company in
excess of $60,000.
<TABLE>
<CAPTION>
INDEBTEDNESS AS
OF 12/31/96
(LARGEST
NO. OF SHARES PER SHARE AGGREGATE INTEREST MATURITY
NAME PURCHASED(#) PRICE($) PRINCIPAL($) INDEBTEDNESS)($) RATE(%) DATE
- --------------------------------------------- ------------- --------- --------- --------------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Wesley D. Sterman, M.D....................... 2,540,000 0.004 10,000(1) 13,877 7.00 03/01/97
20,000 0.062 1,250(1) 1,475 6.00 03/01/99
640,000 0.375 240,000 260,243 6.18 02/28/02
Robert J. Chin, Ph.D......................... 136,000 0.375 51,000 55,302 6.18 12/31/99
10,000(2) 10,000 0.00 12/31/99
Hanson S. Gifford, III(3).................... 176,000 0.062 11,000 0 6.00 07/27/98
176,000 0.375 66,000 71,567 6.18 07/20/03
Steven E. Johnson............................ 192,000 0.375 72,000 78,073 6.18 08/23/99
176,000 0.375 66,000 71,567 6.18 08/23/04
Casey M. Tansey(4)........................... 208,000 0.781 162,500 172,364 6.02 12/11/00
120,000 0.781 93,750 99,847 6.45 12/11/05
</TABLE>
- ------------------------
(1) The Company loaned $10,000 to Dr. Sterman on March 1, 1992, to purchase
2,540,000 shares of Common Stock and $1,250 on March 1, 1994, to purchase
20,000 shares of Common Stock.
(2) On June 5, 1995, the Company made a $10,000 unsecured loan to Dr. Chin at no
interest for relocation expenses.
(3) On July 27, 1993, the Company loaned $11,000 to Mr. Gifford for the purchase
of 176,000 shares of Common Stock. Mr. Gifford repaid this loan plus accrued
interest of $2,257 on September 29, 1996.
(4) The loans from the Company to Mr. Tansey were made on December 28, 1995.
SEVERANCE ARRANGEMENTS
On June 12, 1996, the Company entered into an agreement with Randall S.
Livingston, the Company's then Vice President, Finance and Chief Financial
Officer regarding Mr. Livingston's termination of employment. The agreement
provided for the continuation of Mr. Livingston's employment at full pay through
December 31, 1996 and with continued vesting of his shares of restricted stock,
with a substantially reduced time commitment, and a lump sum payment of $5,000
in consideration of Mr. Livingston's release of all potential claims against the
Company and its officers and directors.
ANNUAL REPORT
A copy of the Annual Report of the Company for the fiscal year ended
December 31, 1996, has been mailed concurrently with this Proxy Statement to all
stockholders entitled to notice of and to vote at the Annual Meeting.
FORM 10-K
The Company filed an Annual Report on Form 10-K with the SEC. Stockholders
may obtain a copy of this report, as amended, without charge, by writing to the
Company's executive offices at 200 Chesapeake Drive, Redwood City, California
94063, Attention: Investor Relations.
28
<PAGE>
OTHER MATTERS
Management does not know of any matters to be presented at this Annual
Meeting other than those set forth herein and in the Notice accompanying this
Proxy Statement.
THE BOARD OF DIRECTORS
OF HEARTPORT, INC.
April 30, 1997
Redwood City, California
29
<PAGE>
HEARTPORT, INC.
ANNUAL MEETING OF STOCKHOLDERS
MAY 28, 1997
P
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
R
O The undersigned hereby appoints WESLEY D. STERMAN, M.D. and RICHARD B.
BREWER, and each or either of them, as Proxies of the undersigned, with
X full power of substitution, and hereby authorizes them to represent and
to vote, as designated in this proxy, all of the shares of Common Stock of
Y HEARTPORT, INC., held of record by the undersigned on March 31, 1997, at
the Annual Meeting of Stockholders of Heartport, Inc. to be held May 28,
1997, or at any adjournment or postponement thereof.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL NUMBERS 1, 2, 3
AND 4. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS SPECIFIED ON
THE REVERSE SIDE. THIS PROXY WILL BE VOTED FOR PROPOSAL NUMBERS 1, 2, 3
AND 4 IF NO SPECIFICATION IS MADE.
------------
|SEE REVERSE|
CONTINUED AND TO BE SIGNED ON REVERSE SIDE | SIDE |
------------
<PAGE>
[LOGO]
Dear Stockholder:
We are pleased to announce Heartport, Inc.'s first Annual Meeting of
Stockholders. The meeting will take place at 2:00 p.m. on May 28, 1997 at the
Hotel Sofitel in Redwood City, California.
Even if you are able to attend the meeting, please review the enclosed
material and cast your votes below.
Your vote is important to us. Please mark the boxes on the proxy card to
indicate how your shares will be voted. Then sign the card, detach it, and
return your proxy in the enclosed postage paid envelope.
Thank you in advance for your prompt consideration of these matters.
Regards,
Heartport, Inc.
DETACH HERE
PLEASE MARK
/ X / VOTES AS IN
THIS EXAMPLE.
1. ELECTION OF DIRECTORS
NOMINEES: Frank M. Fischer, Petri T. Vainio, M.D.
/ / FOR / / WITHHELD
MARK HERE
/ / ________________________________________ FOR ADDRESS / /
For both nominees except as noted above CHANGE AND
NOTE BELOW
2. AMENDMENT TO THE 1996 STOCK OPTION PLAN.
/ / FOR / / AGAINST / / ABSTAIN
3. AMENDMENT TO THE EMPLOYEE STOCK PURCHASE PLAN.
/ / FOR / / AGAINST / / ABSTAIN
4. RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS.
/ / FOR / / AGAINST / / ABSTAIN
5. In their discretion, the Proxies are authorized to vote upon such
other matters as may properly come before the meeting.
PLEASE SIGN, DATE, AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.
Please sign exactly as your name(s) is (are) shown on the share certificate
to which the Proxy applies. When shares are held by joint tenants, both
should sign. When signing as an attorney, executor, administrator, trustee
or guardian, please give full title as such. If a corporation, please sign
in full corporate name by President or other authorized officer. If a
partnership, please sign in partnership name by authorized person.
Signature: ________________ date: ______________
Signature: ________________ date: ______________
